# Antiseizure Medication (ASM) Choice Protocol

[![Evidence-Based](https://img.shields.io/badge/Evidence-ILAE%20%7C%20AAN%20%7C%20NICE-blue)](https://www.ilae.org)
[![Last Updated](https://img.shields.io/badge/Updated-December%202025-green)]()
[![Version](https://img.shields.io/badge/Version-1.0-orange)]()

Clinical guidelines for antiseizure medication selection and management across all patient populations and seizure types.

---

## Quick Navigation

| Section | Description |
|---------|-------------|
| [1. Introduction](docs/01-introduction.md) | Purpose, terminology, general principles |
| [2. Seizure Classification](docs/02-seizure-classification.md) | ILAE 2017 classification, epilepsy syndromes |
| [3. First-Line ASM Selection](docs/03-first-line-selection.md) | ASM choice by seizure type with evidence levels |
| [4. Special Populations](docs/04-special-populations.md) | Pregnancy, elderly, renal/hepatic impairment, comorbidities |
| [5. Status Epilepticus](docs/05-status-epilepticus.md) | Emergency treatment protocol with dosing |
| [6. Drug Interactions](docs/06-drug-interactions.md) | CYP450 effects, ASM-ASM interactions |
| [7. Adverse Effects](docs/07-adverse-effects.md) | Side effect profiles, genetic testing |
| [8. Dosing Guidelines](docs/08-dosing-guidelines.md) | Adult dosing, therapeutic drug monitoring |
| [9. Monitoring Parameters](docs/09-monitoring.md) | Baseline and ASM-specific monitoring |
| [10. Treatment Algorithm](docs/10-treatment-algorithm.md) | Step-by-step treatment approach |
| [11. References](docs/11-references.md) | Evidence sources and citations |
| [Appendices](docs/12-appendices.md) | Abbreviations, evidence levels |

---

## Quick Reference Tables

### ASM Selection by Seizure Type

| Seizure Type | First Choice | Alternatives | Avoid |
|--------------|--------------|--------------|-------|
| **Focal** | Lamotrigine, Levetiracetam | OXC, CBZ, LCM, ZNS | - |
| **Focal (elderly)** | Lamotrigine, Levetiracetam, Gabapentin | Lacosamide | PHT, PB, CBZ |
| **GTC** | Valproate (males), LEV/LTG (females) | TPM, ZNS, PER | - |
| **Absence** | Ethosuximide, Valproate | Lamotrigine | CBZ, GBP, PHT, OXC |
| **Myoclonic** | Valproate, Levetiracetam | ZNS, TPM, CLB | CBZ, GBP, PHT, OXC, LTG* |
| **Tonic/Atonic** | Lamotrigine, Valproate | Rufinamide, Clobazam | - |
| **Pregnancy** | Levetiracetam, Lamotrigine | Oxcarbazepine | VPA, TPM |

*LTG may exacerbate myoclonic seizures in some patients

### Teratogenicity Risk (2024 Data)

| Risk Level | ASM | MCM Rate |
|------------|-----|----------|
| **Lowest** | Levetiracetam, Lamotrigine | 2-3% |
| **Low** | Oxcarbazepine | 2-3% |
| **Moderate** | Carbamazepine | 4-6% |
| **High** | Topiramate | 3-5% + 2.5x ID risk |
| **Highest** | Valproate | 5-15% + 30-40% NDD |

### Status Epilepticus Protocol

```
0-5 min   → Stabilization (ABCs, IV, glucose)
5-20 min  → Benzodiazepine (Lorazepam 0.1 mg/kg IV OR Midazolam 10 mg IM)
20-40 min → Second-line (Fosphenytoin/Valproate/Levetiracetam)
40-60 min → Refractory SE (anesthetic therapy)
>60 min   → Super-refractory SE (ICU, continuous EEG)
```

---

## Evidence Sources

- **ILAE** - International League Against Epilepsy Guidelines
- **AAN/AES** - American Academy of Neurology / American Epilepsy Society (2018, reaffirmed 2024)
- **NICE NG217** - UK National Institute for Health and Care Excellence (2022, reaffirmed 2025)
- **SANAD II Trial** - Lamotrigine vs levetiracetam for focal epilepsy (Lancet 2021)
- **ESETT Trial** - Status epilepticus treatment (NEJM 2019)

---

## Full Protocol

For the complete protocol in a single document, see [ASM_Choice_Protocol.md](ASM_Choice_Protocol.md).

---

## Disclaimer

This protocol is intended as a clinical reference and should be used in conjunction with clinical judgment and individual patient assessment. Always consult current prescribing information and local formulary guidelines.

---

**Document Control:**
- Version: 1.0
- Created: December 2025
- Review Date: December 2026
